IL222711B - Vaccines based on bioconjugation of capsular Gram-positive bacteria - Google Patents

Vaccines based on bioconjugation of capsular Gram-positive bacteria

Info

Publication number
IL222711B
IL222711B IL222711A IL22271112A IL222711B IL 222711 B IL222711 B IL 222711B IL 222711 A IL222711 A IL 222711A IL 22271112 A IL22271112 A IL 22271112A IL 222711 B IL222711 B IL 222711B
Authority
IL
Israel
Prior art keywords
positive bacteria
bioconjugate vaccines
capsular
gram
capsular gram
Prior art date
Application number
IL222711A
Other languages
English (en)
Hebrew (he)
Other versions
IL222711A0 (en
Original Assignee
Glaxosmithkline Biologicals Sa
Glycovaxyn Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa, Glycovaxyn Ag filed Critical Glaxosmithkline Biologicals Sa
Publication of IL222711A0 publication Critical patent/IL222711A0/en
Publication of IL222711B publication Critical patent/IL222711B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IL222711A 2010-05-06 2012-10-25 Vaccines based on bioconjugation of capsular Gram-positive bacteria IL222711B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33217010P 2010-05-06 2010-05-06
PCT/EP2011/057111 WO2011138361A1 (en) 2010-05-06 2011-05-04 Capsular gram-positive bacteria bioconjugate vaccines

Publications (2)

Publication Number Publication Date
IL222711A0 IL222711A0 (en) 2012-12-31
IL222711B true IL222711B (en) 2018-10-31

Family

ID=44902091

Family Applications (1)

Application Number Title Priority Date Filing Date
IL222711A IL222711B (en) 2010-05-06 2012-10-25 Vaccines based on bioconjugation of capsular Gram-positive bacteria

Country Status (20)

Country Link
US (3) US8871491B2 (enExample)
EP (2) EP2566507B1 (enExample)
JP (2) JP6339366B2 (enExample)
KR (2) KR101916290B1 (enExample)
CN (1) CN103079591B (enExample)
AU (2) AU2011249839B2 (enExample)
CA (1) CA2798381C (enExample)
CY (1) CY1119895T1 (enExample)
DK (1) DK2566507T3 (enExample)
ES (2) ES2844596T3 (enExample)
HR (1) HRP20180064T1 (enExample)
HU (1) HUE037956T2 (enExample)
IL (1) IL222711B (enExample)
LT (1) LT2566507T (enExample)
NO (1) NO2566507T3 (enExample)
PL (1) PL2566507T3 (enExample)
PT (1) PT2566507T (enExample)
SG (1) SG185433A1 (enExample)
SI (1) SI2566507T1 (enExample)
WO (1) WO2011138361A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1481057T3 (da) * 2002-03-07 2006-05-15 Eidgenoess Tech Hochschule System og fremgangsmåde til fremstilling af rekombinante glycosylerede proteiner i en prokaryot vært
SI2257307T1 (sl) 2008-02-20 2018-09-28 Glaxosmithkline Biologicals S.A. Biokonjugati, izdelani iz rekombinantnih N-glikoziliranih proteinov iz prokariontskih celic
NO2501406T3 (enExample) * 2009-11-19 2018-05-19
WO2013159234A1 (en) * 2012-04-27 2013-10-31 The Governors Of The University Of Alberta Glycoengineered outer membrane vesicles and use thereof as vaccines
CA2879272A1 (en) 2012-07-16 2014-01-23 Robert G.K. DONALD Saccharides and uses thereof
EP2877205A4 (en) 2012-07-26 2016-04-06 Jackson H M Found Military Med VACCINE WITH A MULTIMED FUSION PROTEIN AND IMMUNOTHERAPY
KR20150068998A (ko) 2012-10-12 2015-06-22 글리코박신 아게 숙주 세포 변형 방법
EP2917351B1 (en) 2012-11-07 2018-12-19 GlaxoSmithKline Biologicals S.A. Production of recombinant vaccine in e. coli by enzymatic conjugation
US9931392B2 (en) 2013-01-18 2018-04-03 London School Of Hygiene And Tropical Medicine Glycosylation method
GB201301085D0 (en) * 2013-01-22 2013-03-06 London School Hygiene & Tropical Medicine Glycoconjugate Vaccine
BR112016007727A8 (pt) * 2013-10-11 2018-01-30 Glycovaxyn Ag célula hospedeira, e, método para produzir uma proteína n-glicosilada.
CN106163550A (zh) * 2013-12-04 2016-11-23 格林考瓦因有限公司 通过大肠杆菌中合成的糖蛋白疫苗预防金黄色葡萄球菌感染
MX378857B (es) * 2014-04-17 2025-03-10 Glaxosmithkline Biologicals Sa Celulas huespedes modificadas y usos de las mismas.
AR104469A1 (es) * 2014-08-08 2017-07-26 Glycovaxyn Ag Células huésped modificadas para su uso en producción de bioconjugados
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10500261B2 (en) 2014-11-05 2019-12-10 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against campylobacter jejuni
JP2017537145A (ja) * 2014-11-05 2017-12-14 ザ ユナイテッド ステイツ オブ アメリカ アズ レプレゼンティッド バイ ザ セクレタリー オブ ザ ネイビーＴｈｅ Ｕｎｉｔｅｄ Ｓｔａｔｅｓ Ｏｆ Ａｍｅｒｉｃａ Ａｓ Ｒｅｐｒｅｓｅｎｔｅｄ Ｂｙ Ｔｈｅ Ｓｅｃｒｅｔａｒｙ Ｏｆ Ｔｈｅ Ｎａｖｙ カンピロバクター・ジェジュニに対する合成抗原コンストラクト
SI3240895T1 (sl) 2014-12-30 2022-04-29 Glaxosmithkline Biologicals S.A. Sestavki in postopki za glikozilacijo proteinov
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3316904A1 (en) * 2015-07-01 2018-05-09 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
GB201712678D0 (en) 2017-08-07 2017-09-20 Glaxosmithkline Biologicals Sa Process for the manipulation of nucleic acids
GB201721582D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
CN108330142B (zh) * 2018-02-09 2021-09-17 河北科技师范学院 一种具有免疫保护作用的美人鱼发光杆菌溶血素Hlych蛋白
GB201802339D0 (en) * 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CN109400704B (zh) * 2018-11-14 2020-07-21 珠海泰诺麦博生物技术有限公司 一种抗金黄色葡萄球菌α-溶血素的抗体及其应用
JP7551618B2 (ja) * 2018-12-12 2024-09-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｏ－結合型グリコシル化のための修飾キャリアタンパク質
EP3908669A4 (en) * 2019-01-11 2023-05-03 Northwestern University SYNTHESIS OF BIOCONJUGATED VACCINES IN PROKARYOT CELL LYSATE
EP3757217A1 (en) 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Methods for protein purification
EP3770269A1 (en) * 2019-07-23 2021-01-27 GlaxoSmithKline Biologicals S.A. Quantification of bioconjugate glycosylation
MX2022001606A (es) 2019-08-09 2022-03-11 Glaxosmithkline Biologicals Sa Enzimas de oligosacariltransferasa pglb mutada.
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
CN112575041B (zh) * 2019-09-30 2022-12-13 江南大学 一种混合碳源高效发酵生产phb的工程菌及其应用
US20230226175A1 (en) * 2020-06-25 2023-07-20 Glaxosmithkline Biologicals Sa Modified exotoxin a proteins
CN114085255B (zh) * 2020-08-24 2023-08-29 山东大学 一种苏黎世克罗诺杆菌5型脂多糖o-抗原寡糖片段及其制备方法与应用
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
US12680087B2 (en) 2021-02-11 2026-07-14 Glaxosmithkline Biologicals Sa Mutated PGLB oligosaccharyltransferase enzymes
EP4452308A1 (en) 2021-12-22 2024-10-30 GlaxoSmithKline Biologicals S.A. Vaccine
CN117940555B (zh) * 2022-06-30 2025-05-30 上海羽冠生物技术有限公司 荚膜减少的活细菌菌株
GB202302579D0 (en) 2023-02-23 2023-04-12 Glaxosmithkline Biologicals Sa Immunogenic composition
KR20260052081A (ko) 2023-08-09 2026-04-17 글락소스미스클라인 바이오로지칼즈 에스.에이. 변형된 단백질
KR20260051063A (ko) 2023-08-09 2026-04-15 글락소스미스클라인 바이오로지칼즈 에스.에이. 변형된 단백질
CN117771264B (zh) * 2023-11-27 2024-06-25 山东省农业科学院畜牧兽医研究所 circHIF1α在制备抵御细菌感染的新型疫苗中的应用
WO2025172892A1 (en) 2024-02-16 2025-08-21 Glaxosmithkline Biologicals Sa Modified proteins and methods
CN120005900B (zh) * 2025-01-21 2026-01-06 浙江大学 FaCP5L1和FaCP5L3基因及其在调控果实成熟和采后保鲜品质中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1900A (en) 1840-12-14 Machine for extracting stumps
EP0170204B1 (de) 1984-08-01 1991-09-25 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Neue genetische Sequenzen, die durch sie codierten Interferon-Peptide vom Typ I und diese sie produzierende Organismen
US5643758A (en) 1987-03-10 1997-07-01 New England Biolabs, Inc. Production and purification of a protein fused to a binding protein
AU6663294A (en) 1993-05-14 1994-12-12 Upjohn Company, The Cloned dna encoding a udp-galnac:polypeptide,n-acetylgalactos aminyltransferase
US6503744B1 (en) 1999-02-01 2003-01-07 National Research Council Of Canada Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics
EP1399538A2 (en) 1999-03-02 2004-03-24 Human Genome Sciences, Inc. Engineering intracellular sialylation pathways
NZ522320A (en) 2000-05-12 2007-03-30 Neose Technologies Inc In vitro modification of glycosylation patterns of recombinant glycopeptides
EP2028275A3 (en) 2000-06-30 2009-05-06 VIB vzw Protein glycosylation modification in pichia pastoris
JP4727927B2 (ja) 2002-03-07 2011-07-20 アイトゲネシシェ・テッヒニシェ・ホーホシューレ・チューリッヒ 原核宿主における組換えグリコシル化タンパク質産生のためのシステムおよび方法
DK1481057T3 (da) 2002-03-07 2006-05-15 Eidgenoess Tech Hochschule System og fremgangsmåde til fremstilling af rekombinante glycosylerede proteiner i en prokaryot vært
CN1671722A (zh) 2002-08-01 2005-09-21 加拿大国家研究院 弯曲菌的聚糖和糖肽
EP2657251B1 (en) 2004-05-24 2018-03-21 The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services Live, oral vaccine for protection against Shigella dysenteriae serotype 1
ES2535084T3 (es) * 2005-05-11 2015-05-05 Eth Zurich Proteínas N-glicosiladas recombinantes procedentes de células procariotas
NZ570805A (en) 2006-03-30 2011-10-28 Glaxosmithkline Biolog Sa Vaccine comprising Type 5 and Type 8 capsular polysaccharides from Staphyloccocus aureus
CN102037004A (zh) * 2008-01-08 2011-04-27 生物种属学股份公司 使用寡糖基转移酶的多肽的糖缀合
SI2257307T1 (sl) * 2008-02-20 2018-09-28 Glaxosmithkline Biologicals S.A. Biokonjugati, izdelani iz rekombinantnih N-glikoziliranih proteinov iz prokariontskih celic

Also Published As

Publication number Publication date
WO2011138361A1 (en) 2011-11-10
LT2566507T (lt) 2018-02-12
KR20180021219A (ko) 2018-02-28
US9585950B2 (en) 2017-03-07
AU2011249839A1 (en) 2012-11-29
US20170128559A1 (en) 2017-05-11
CA2798381A1 (en) 2011-11-10
SI2566507T1 (en) 2018-04-30
IL222711A0 (en) 2012-12-31
PL2566507T3 (pl) 2018-05-30
HRP20180064T1 (hr) 2018-02-23
DK2566507T3 (da) 2018-01-29
CA2798381C (en) 2020-10-06
EP3281639A1 (en) 2018-02-14
JP6435583B2 (ja) 2018-12-12
KR101916290B1 (ko) 2018-11-09
US10307473B2 (en) 2019-06-04
JP2017036303A (ja) 2017-02-16
HUE037956T2 (hu) 2018-09-28
US20150010592A1 (en) 2015-01-08
EP2566507B1 (en) 2017-11-22
CN103079591A (zh) 2013-05-01
PT2566507T (pt) 2018-02-06
US8871491B2 (en) 2014-10-28
SG185433A1 (en) 2012-12-28
ES2657588T3 (es) 2018-03-06
KR20130063510A (ko) 2013-06-14
US20110274720A1 (en) 2011-11-10
EP3281639B1 (en) 2020-11-11
AU2016208265A1 (en) 2016-08-11
NO2566507T3 (enExample) 2018-04-21
JP6339366B2 (ja) 2018-06-06
CY1119895T1 (el) 2018-06-27
EP2566507A1 (en) 2013-03-13
CN103079591B (zh) 2017-07-28
ES2844596T3 (es) 2021-07-22
JP2013524844A (ja) 2013-06-20
AU2011249839B2 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
IL222711A0 (en) Capsular gram-positive bacteria bioconjugate vaccines
IL222680A0 (en) Synthetic nanocarrier combination vaccines
IL223206A0 (en) Vaccine formulations
GB201015132D0 (en) Vaccine composition
GB201119938D0 (en) Blower arrangement
GB201019086D0 (en) Bacterial methods
GB201014965D0 (en) Vaccine
ZA201301950B (en) Bvdv vaccine
GB0907935D0 (en) Vaccines
GB201014904D0 (en) Travel pillow
GB0900455D0 (en) Vaccine
GB201013006D0 (en) Vaccine
GB201006324D0 (en) Vaccine
GB201007379D0 (en) Bacterial secretion
ZA201302154B (en) Vaccine
GB2515669B (en) Bacterial vaccine
GB201106170D0 (en) Bacterial vaccine
GB201008788D0 (en) Vaccines
GB201008786D0 (en) Vaccines
GB201008793D0 (en) vaccines
GB201008795D0 (en) Vaccines
GB201012283D0 (en) Vaccine
GB201007588D0 (en) Vaccine
GB201007589D0 (en) Vaccine
GB201009277D0 (en) Novel vaccine

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed